Grifols reported EUR320.45M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Alaunos Therapeutics USD 447K 138K Mar/2026
Arca Biopharma USD 2.23M 1.08M Dec/2025
aTyr Pharma USD 82.26M 77.46M Dec/2025
Bio Path USD 199K 300K Sep/2025
Brainstorm Cell Therapeutics USD 1.39M 326K Dec/2025
Capricor Therapeutics USD 1.92M 446.47K Dec/2025
Cara Therapeutics USD 2.19M 2.45M Sep/2025
Esperion Therapeutics USD 39.42M 456K Dec/2025
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Grifols EUR 320.45M 12.65M Dec/2025
Immunic USD 3.45M 451K Dec/2025
Infinity Pharmaceuticals USD 3.75M 2.19M Jun/2023
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
TherapeuticsMD USD 1.23M 90K Jun/2024